Objectives
Gout, a common form of arthritis, can be successfully controlled with pharmacotherapy and thus an ideal model for examining chronic disease management. Our aim was to examine treatment of gout evaluated in accordance with general management guidelines for gout as applied to Australian residential aged care facilities (RACFs).
Methods
Electronic health record data linked with aged care clinical notes and electronic medication administration information (11,548 residents in 68 RACFs, over 65 years) was interrogated to identify people with gout, other chronic conditions and gout medication use. Outcomes examined: 1) proportion receiving urate-lowering therapy (ULT) (preventative medication) and/or colchicine/non-steroidal anti-inflammatory drugs (NSAID) (treat gout flares); 2) number of ULT and colchicine/NSAID treatment episodes (periods of continuous days of medication use); 3) duration of these medication uses.
Results
Cohort included 1179 residents with gout, of which 62% used a ULT, with median of one episode of use for a very short duration (median=4 days, median of use in total (i.e. repeated use) =52 days). Among residents with gout, 9% also used colchicine or an NSAID. Female residents were less likely to receive ULT and for shorter periods.
Conclusion
Nearly a third of residents with gout did not receive ULTs. In those receiving ULT, recurrent short courses were common. Overall, management of gout in aged care residents appears to be suboptimal, largely due to intermittent and short exposure to ULT, and with female residents at greater risk of poor gout management.
Lay summary
What does this mean for patients ?
Residents living in aged care facilities are at risk of receiving suboptimal pharmacological management of their gout. Instead of receiving the recommended long-term urate-lowering therapies, aged care residents have intermittent short exposures to these medications, which may not elicit the appropriate protection against painful gout flares. Female aged care residents are at greater risk of receiving poor gout management. Further research exploring the reasons why gout management is not concordant to guidelines within the residential aged care setting is required. This will ensure residents receive appropriate gout management to minimise the debilitating painful effects of gout. This study also demonstrates the ability to use routinely collected patient data to improve delivery of care in the aged care setting.